CRL
$153.71
Charles River Laboratories International, Inc.
Recent News
3 Reasons CRL is Risky and 1 Stock to Buy Instead
Over the past six months, Charles River Laboratories has been a great trade, beating the S&P 500 by 7.5%. Its stock price has climbed to $168.91, representing a healthy 10.5% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
IQVIA Expands In Vitro Discovery Footprint As Shares Face Pressure
IQVIA Holdings (NYSE:IQV) has agreed to acquire discovery services assets from Charles River Laboratories. The deal adds in vitro discovery capabilities across five additional sites to IQVIA's existing network. The transaction is aimed at expanding IQVIA's role in early stage drug discovery services and related data offerings. IQVIA Holdings, trading at $170.93, has had a mixed share price record recently, with a 7 day return of a 1.7% decline and a 30 day return of an 8.8% decline. Over...
Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies (NYSE:A) while trimming its price target on Icon PLC (NASDAQ:ICLR) following a turbulent earnings season for the sector. Alongside those moves, the firm named Agilent its top tools pick, Natera (NASDAQ:NTRA) its top diagnostics ... Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth
IQVIA Holdings Inc. (NYSE:IQV) is one of the 11 Best Affordable Growth Stocks to Buy Now. On March 3, analysts at RBC Capital initiated coverage of IQVIA Holdings Inc. (NYSE:IQV) with an Outperform rating and a $221 price target. According to RBC Capital analyst Ryan Halsted, the company is making significant progress in clinical trial […]
Charles River Laboratories International (CRL) Gains on Strong Results and Resilient Drug Outsourcing Demand
Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund advanced +3.04% in the fourth quarter of 2025, outperforming the Russell Midcap Value Index’s +1.42% and the Russell Midcap Index’s +0.16% returns as U.S. equities posted a modest gain […]